NCT01188538

Brief Summary

The purpose of this study is to evaluate the antibacterial activity of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) on P. acnes compared to that of Benzoyl Peroxide 2.5% Gel.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Mar 2010

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2010

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
23 days until next milestone

First Submitted

Initial submission to the registry

August 24, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 25, 2010

Completed
11 months until next milestone

Results Posted

Study results publicly available

July 7, 2011

Completed
Last Updated

February 18, 2021

Status Verified

July 1, 2011

Enrollment Period

5 months

First QC Date

August 24, 2010

Results QC Date

June 9, 2011

Last Update Submit

February 16, 2021

Conditions

Keywords

P. acnes, Acne vulgaris

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline (Log10 Cfu/cm²) in Count of Follicular P. Acnes

    Quantitative bacterial examinations were performed on the subjects' face during the study. These samplings were performed using a method to quantify the follicular microbiological flora of the skin (at Baseline and Week 12 visits).This method consists of a technique allowing the extraction of the outermost layer of epidermis from hair follicle on the cheek and to culture the samplings in order to have the number of P. acnes. Outcome measure = Change from baseline (Log10 cfu/cm²) in count of Follicular P. acnes at end of the study.

    Week 12

Secondary Outcomes (1)

  • Percent Change (%) in Inflammatory Lesion Counts

    Week 12

Study Arms (2)

Epiduo gel

EXPERIMENTAL

* Dose or Concentration:Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel. * Mode and Frequency of Administration:Topical to the face, once daily application in the evening. * Duration of Treatment:12 weeks

Drug: Epiduo gel

BPO gel

ACTIVE COMPARATOR

* Dose or Concentration:Adapalene 0% / Benzoyl Peroxide 2.5% Gel. * Mode and Frequency of Administration:Topical to the face, once daily application in the evening. * Duration of Treatment:12 weeks

Drug: BPO

Interventions

Once daily application on the face in the evening for 12 weeks

Also known as: Epiduo
Epiduo gel
BPODRUG

Once daily application on the face in the evening for 12 weeks

BPO gel

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects with facial acne,
  • Subjects with high levels of P. acnes counts on the forehead

You may not qualify if:

  • Female Subjects who are pregnant, nursing or planning a pregnancy during the study,
  • Subjects with acne conglobata, acne fulminans, secondary acne
  • Subjects with known or suspected allergy to one of the test product

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dermatologiczna Klinika Uzdrowiskowa

Iwonicz-Zdrój, 38-440, Poland

Location

Related Links

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Adapalene, Benzoyl Peroxide Drug Combination

Condition Hierarchy (Ancestors)

Acneiform EruptionsSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

Benzoyl PeroxideBenzoatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsAdapaleneNaphthalenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsDrug CombinationsPharmaceutical Preparations

Results Point of Contact

Title
Farzaneh SIDOU
Organization
Galderma

Study Officials

  • Andrzej LANGNER, Professor

    Dermatologiczna Klinika Uzdrowiskowa, IWOLANG Sp. z o.o. , Zespół Naukowo-Kliniczny, IWONICZ ZDRÓJ - POLAND

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 24, 2010

First Posted

August 25, 2010

Study Start

March 1, 2010

Primary Completion

August 1, 2010

Study Completion

August 1, 2010

Last Updated

February 18, 2021

Results First Posted

July 7, 2011

Record last verified: 2011-07

Locations